TESTBANK
,Table of Contents
dfdf dfdf
Chapter 01: The Nursing Process and Drug Therapy.......................................................................... 4
dfdf dfdf dfdf dfdf dfdf dfdf dfdf
Chapter 02: Pharmacologic Principles ..................................................................................................... 8
dfdf dfdf dfdf
Chapter 03: Lifespan Considerations .................................................................................................... 14
dfdf dfdf dfdf
Chapter 04: Cultural, Legal, and Ethical Considerations .................................................................... 20
dfdf dfdf dfdf dfdf dfdf dfdf
Chapter 05: Medication Errors: Preventing and Responding ............................................................. 26
dfdf dfdf dfdf dfdf dfdf dfdf
Chapter 06: Patient Education and Drug Therapy.............................................................................. 29
dfdf dfdf dfdf dfdf dfdf dfdf
Chapter 07: Over-the-Counter Drugs and Herbal and Dietary Supplements ................................... 34
dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf
Chapter 08: Gene Therapy and Pharmacogenomics........................................................................... 38
dfdf dfdf dfdf dfdf dfdf
Chapter 09: Photo Atlas of Drug Administration............................................................................... 41
dfdf dfdf d fdf dfdf dfdf dfdf
Chapter 10: Analgesic Drugs ................................................................................................................. 50
dfdf dfdf dfdf
Chapter 11: General and Local Anesthetics ....................................................................................... 57
dfdf dfdf dfdf dfdf dfdf
Chapter 12: Central Nervous System Depressants and Muscle Relaxants........................................ 61
dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf
Chapter 13: Central Nervous System Stimulants and Related Drugs .............................................. 66
dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf
Chapter 14: Antiepileptic Drugs ............................................................................................................ 70
dfdf dfdf dfdf
Chapter 15: Antiparkinson Drugs........................................................................................................... 76
dfdf dfdf dfdf
Chapter 16: Psychotherapeutic Drugs ................................................................................................... 81
dfdf dfdf dfdf
Chapter 17: Substance Use Disorder.................................................................................................... 88
dfdf dfdf dfdf dfdf
Chapter 18: Adrenergic Drugs ............................................................................................................... 93
dfdf dfdf dfdf
Chapter 19: Adrenergic-Blocking Drugs ................................................................................................ 98
dfdf dfdf dfdf
Chapter 20: Cholinergic Drugs ............................................................................................................ 103
dfdf dfdf dfdf
Chapter 21: Cholinergic-Blocking Drugs .............................................................................................. 108
dfdf dfdf dfdf
Chapter 22: Antihypertensive Drugs ................................................................................................... 113
dfdf dfdf dfdf
Chapter 23: Antianginal Drugs ............................................................................................................ 119
dfdf dfdf dfdf
Chapter 24: Heart Failure Drugs ........................................................................................................ 125
dfdf dfdf dfdf dfdf
Chapter 25: Antidysrhythmic Drugs .................................................................................................... 131
dfdf dfdf dfdf
Chapter 26: Coagulation Modifier Drugs ........................................................................................... 137
dfdf dfdf dfdf dfdf
Chapter 27: Antilipemic Drugs ............................................................................................................ 143
dfdf dfdf dfdf
Chapter 28: Diuretic Drugs.................................................................................................................. 148
dfdf dfdf dfdf
Chapter 29: Fluids and Electrolytes ................................................................................................... 154
dfdf dfdf dfdf dfdf
Chapter 30: Pituitary Drugs ................................................................................................................. 160
dfdf dfdf dfdf
,Chapter 31: Thyroid and Antithyroid Drugs ...................................................................................... 163
dfdf dfdf dfdf dfdf dfdf
Chapter 32: Antidiabetic Drugs ........................................................................................................... 168
dfdf dfdf dfdf
Chapter 33: Adrenal Drugs .................................................................................................................. 177
dfdf dfdf dfdf
Chapter 34: Women’s Health Drugs .................................................................................................. 181
dfdf dfdf dfdf dfdf
Chapter 35: Men’s Health Drugs........................................................................................................ 188
dfdf dfdf dfdf dfdf
Chapter 36: Antihistamines, Decongestants, Antitussives, and Expectorants .................................. 193
dfdf dfdf dfdf dfdf dfdf dfdf
Chapter 37: Respiratory Drugs............................................................................................................ 198
dfdf dfdf dfdf
Chapter 38: Antibiotics Part 1 ............................................................................................................ 204
dfdf dfdf dfdf dfdf
Chapter 39: Antibiotics Part 2 ............................................................................................................ 211
dfdf dfdf dfdf dfdf
Chapter 40: Antiviral Drugs ................................................................................................................. 216
dfdf dfdf dfdf
Chapter 41: Antitubercular Drugs........................................................................................................ 221
dfdf dfdf dfdf
Chapter 42: Antifungal Drugs .............................................................................................................. 226
dfdf dfdf dfdf
Chapter 43: Antimalarial, Antiprotozoal, and Anthelmintic Drugs ................................................... 231
dfdf dfdf dfdf dfdf dfdf dfdf
Chapter 44: Anti-inflammatory and Antigout Drugs ......................................................................... 236
dfdf dfdf dfdf dfdf dfdf
Chapter 45: Antineoplastic Drugs Part 1: Cancer Overview and Cell Cycle–Specific Drugs ......... 242
dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf
Chapter 46: Antineoplastic Drugs Part 2: Cell Cycle–Nonspecific Drugs and Miscellaneous Drugs248
dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf
Chapter 47: Biologic Response–Modifying and Antirheumatic Drugs ............................................... 253
dfdf dfdf dfdf dfdf dfdf dfdf
Chapter 48: Immunosuppressant Drugs.............................................................................................. 258
dfdf dfdf dfdf
Chapter 49: Immunizing Drugs............................................................................................................ 263
dfdf dfdf dfdf
Chapter 50: Acid-Controlling Drugs ..................................................................................................... 268
dfdf dfdf dfdf
Chapter 51: Bowel Disorder Drugs .................................................................................................... 274
dfdf dfdf dfdf dfdf
Chapter 52: Antiemetic and Antinausea Drugs ................................................................................ 281
dfdf dfdf dfdf dfdf dfdf
Chapter 53: Vitamins and Minerals ................................................................................................... 286
dfdf dfdf dfdf dfdf
Chapter 54: Anemia Drugs .................................................................................................................. 292
dfdf dfdf dfdf
Chapter 55: Nutritional Supplements ................................................................................................. 299
dfdf dfdf dfdf
Chapter 56: Dermatologic Drugs ......................................................................................................... 304
dfdf dfdf dfdf
Chapter 57: Ophthalmic Drugs............................................................................................................ 310
dfdf dfdf dfdf
Chapter 58: Otic Drugs ....................................................................................................................... 315
dfdf dfdf dfdf
, Chapter 01: The Nursing Process and Drug Therapy
dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf d f d f
4
d f d f
Chapter 01: The Nursing Process and Drug Therapy
dfdf dfdf dfdf dfdf dfdf dfdf dfdf
MULTIPLE CHOICE dfdf
1. The nurse is writing a nursing diagnosis for a plan of care for a patient who
dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf
has been newly diagnosed with type 2 diabetes. Which statement reflects the
dfdf dfdf dfdf df df df df dfdf dfdf df df df df df df dfdf df df
correct format for a nursing diagnosis?
dfdf df df dfdf dfdf dfdf dfdf
a. Anxiety
b. Anxiety related to new drug therapy dfdf df df df df df df dfdf
c. Anxiety related to anxious feelings about drug therapy, as evidenced by
dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf
statements such as “I’m upset about having to test my blood sugars.”
dfdf dfdf df df df df dfdf dfdf df df df df df df dfdf dfdf dfdf
d. Anxiety related to new drug therapy, as evidenced by statements such
dfdf dfdf dfdf dfdf dfdf dfdf dfdf df df dfdf dfdf
as “I’m upset about having to test my blood sugars.”
dfdf dfdf dfdf dfdf dfdf df df df df dfdf dfdf dfdf
ANS: df df D
Formulation of nursing diagnoses is usually a three-step process. “Anxiety” is missing
dfdf dfdf dfdf dfdf dfdf df df dfdf dfdf dfdf dfdf dfdf
the “related to” and “as evidenced by” portions of defining characteristics. “Anxiety
dfdf dfdf df df df df dfdf dfdf df df dfdf df df df df dfdf df df
related to new drug therapy” is missing the “as evidenced by” portion of defining
dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf
characteristics. The statement beginning “Anxiety related to anxious feelings” is
dfdf dfdf dfdf dfdf dfdf dfdf df df df df dfdf df df
incorrect because the “related to” section is simply a restatement of the problem
dfdf dfdf df df df df dfdf dfdf df df dfdf dfdf df df dfdf dfdf df df
“anxiety,” not a separate factor related to the response.
dfdf dfdf df df dfdf df df dfdf dfdf df df df df
DIF: COGNITIVE LEVEL: Understanding dfdf dfdf
(Comprehension) TOP:
dfdf NURSING PROCESS: df df d f d f dfdf
Nursing Diagnosis
dfdf df df
MSC: NCLEX: Safe and Effective Care Environment: Management of Care
d f d f dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf
2. The patient is to receive oral guaifenesin (Mucinex) twice a day. Today, the nurse
dfdf dfdf dfdf dfdf df df dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf
was busy and gave the medication 2 hours after the scheduled dose was due.
dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf df df dfdf dfdf dfdf dfdf dfdf
What type of problem does this represent?
dfdf dfdf df df df df dfdf df df dfdf
a. “Right time” dfdf
b. “Right dose” dfdf
c. “Right route” dfdf
d. “Right medication” dfdf
ANS: df df A
“Right time” is correct because the medication was given more than 30 minutes
dfdf df df dfdf df df dfdf dfdf dfdf df df dfdf dfdf df df dfdf
after the scheduled dose was due. “Dose” is incorrect because the dose is not
dfdf df df df df df df dfdf dfdf dfdf df df df df df df dfdf dfdf df df df df
related to the time the medication administration is scheduled. “Route” is incorrect
dfdf df df df df df df dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf
because the route is not affected. “Medication” is incorrect because the medication
dfdf dfdf dfdf dfdf dfdf dfdf dfdf df df dfdf dfdf dfdf df df
ordered will not change.
dfdf dfdf dfdf dfdf
DIF: COGNITIVE LEVEL: Applying dfdf dfdf
(Application) TOP:
dfdf NURSING PROCESS: dfdf d f d f dfdf
Implementation
dfdf
MSC: NCLEX: Safe and Effective Care Environment: Safety and Infection Control
d f d f dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf
3. The nurse has been monitoring the patient’s progress on a new drug regimen since
dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf
the first dose and documenting the patient’s therapeutic response to the medication.
dfdf dfdf dfdf dfdf df df dfdf dfdf dfdf dfdf dfdf dfdf dfdf
Which phase of the nursing process do these actions illustrate?
dfdf df df df df dfdf dfdf dfdf df df dfdf dfdf df df
a. Nursing diagnosis dfdf
,Table of Contents
dfdf dfdf
Chapter 01: The Nursing Process and Drug Therapy.......................................................................... 4
dfdf dfdf dfdf dfdf dfdf dfdf dfdf
Chapter 02: Pharmacologic Principles ..................................................................................................... 8
dfdf dfdf dfdf
Chapter 03: Lifespan Considerations .................................................................................................... 14
dfdf dfdf dfdf
Chapter 04: Cultural, Legal, and Ethical Considerations .................................................................... 20
dfdf dfdf dfdf dfdf dfdf dfdf
Chapter 05: Medication Errors: Preventing and Responding ............................................................. 26
dfdf dfdf dfdf dfdf dfdf dfdf
Chapter 06: Patient Education and Drug Therapy.............................................................................. 29
dfdf dfdf dfdf dfdf dfdf dfdf
Chapter 07: Over-the-Counter Drugs and Herbal and Dietary Supplements ................................... 34
dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf
Chapter 08: Gene Therapy and Pharmacogenomics........................................................................... 38
dfdf dfdf dfdf dfdf dfdf
Chapter 09: Photo Atlas of Drug Administration............................................................................... 41
dfdf dfdf d fdf dfdf dfdf dfdf
Chapter 10: Analgesic Drugs ................................................................................................................. 50
dfdf dfdf dfdf
Chapter 11: General and Local Anesthetics ....................................................................................... 57
dfdf dfdf dfdf dfdf dfdf
Chapter 12: Central Nervous System Depressants and Muscle Relaxants........................................ 61
dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf
Chapter 13: Central Nervous System Stimulants and Related Drugs .............................................. 66
dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf
Chapter 14: Antiepileptic Drugs ............................................................................................................ 70
dfdf dfdf dfdf
Chapter 15: Antiparkinson Drugs........................................................................................................... 76
dfdf dfdf dfdf
Chapter 16: Psychotherapeutic Drugs ................................................................................................... 81
dfdf dfdf dfdf
Chapter 17: Substance Use Disorder.................................................................................................... 88
dfdf dfdf dfdf dfdf
Chapter 18: Adrenergic Drugs ............................................................................................................... 93
dfdf dfdf dfdf
Chapter 19: Adrenergic-Blocking Drugs ................................................................................................ 98
dfdf dfdf dfdf
Chapter 20: Cholinergic Drugs ............................................................................................................ 103
dfdf dfdf dfdf
Chapter 21: Cholinergic-Blocking Drugs .............................................................................................. 108
dfdf dfdf dfdf
Chapter 22: Antihypertensive Drugs ................................................................................................... 113
dfdf dfdf dfdf
Chapter 23: Antianginal Drugs ............................................................................................................ 119
dfdf dfdf dfdf
Chapter 24: Heart Failure Drugs ........................................................................................................ 125
dfdf dfdf dfdf dfdf
Chapter 25: Antidysrhythmic Drugs .................................................................................................... 131
dfdf dfdf dfdf
Chapter 26: Coagulation Modifier Drugs ........................................................................................... 137
dfdf dfdf dfdf dfdf
Chapter 27: Antilipemic Drugs ............................................................................................................ 143
dfdf dfdf dfdf
Chapter 28: Diuretic Drugs.................................................................................................................. 148
dfdf dfdf dfdf
Chapter 29: Fluids and Electrolytes ................................................................................................... 154
dfdf dfdf dfdf dfdf
Chapter 30: Pituitary Drugs ................................................................................................................. 160
dfdf dfdf dfdf
,Chapter 31: Thyroid and Antithyroid Drugs ...................................................................................... 163
dfdf dfdf dfdf dfdf dfdf
Chapter 32: Antidiabetic Drugs ........................................................................................................... 168
dfdf dfdf dfdf
Chapter 33: Adrenal Drugs .................................................................................................................. 177
dfdf dfdf dfdf
Chapter 34: Women’s Health Drugs .................................................................................................. 181
dfdf dfdf dfdf dfdf
Chapter 35: Men’s Health Drugs........................................................................................................ 188
dfdf dfdf dfdf dfdf
Chapter 36: Antihistamines, Decongestants, Antitussives, and Expectorants .................................. 193
dfdf dfdf dfdf dfdf dfdf dfdf
Chapter 37: Respiratory Drugs............................................................................................................ 198
dfdf dfdf dfdf
Chapter 38: Antibiotics Part 1 ............................................................................................................ 204
dfdf dfdf dfdf dfdf
Chapter 39: Antibiotics Part 2 ............................................................................................................ 211
dfdf dfdf dfdf dfdf
Chapter 40: Antiviral Drugs ................................................................................................................. 216
dfdf dfdf dfdf
Chapter 41: Antitubercular Drugs........................................................................................................ 221
dfdf dfdf dfdf
Chapter 42: Antifungal Drugs .............................................................................................................. 226
dfdf dfdf dfdf
Chapter 43: Antimalarial, Antiprotozoal, and Anthelmintic Drugs ................................................... 231
dfdf dfdf dfdf dfdf dfdf dfdf
Chapter 44: Anti-inflammatory and Antigout Drugs ......................................................................... 236
dfdf dfdf dfdf dfdf dfdf
Chapter 45: Antineoplastic Drugs Part 1: Cancer Overview and Cell Cycle–Specific Drugs ......... 242
dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf
Chapter 46: Antineoplastic Drugs Part 2: Cell Cycle–Nonspecific Drugs and Miscellaneous Drugs248
dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf
Chapter 47: Biologic Response–Modifying and Antirheumatic Drugs ............................................... 253
dfdf dfdf dfdf dfdf dfdf dfdf
Chapter 48: Immunosuppressant Drugs.............................................................................................. 258
dfdf dfdf dfdf
Chapter 49: Immunizing Drugs............................................................................................................ 263
dfdf dfdf dfdf
Chapter 50: Acid-Controlling Drugs ..................................................................................................... 268
dfdf dfdf dfdf
Chapter 51: Bowel Disorder Drugs .................................................................................................... 274
dfdf dfdf dfdf dfdf
Chapter 52: Antiemetic and Antinausea Drugs ................................................................................ 281
dfdf dfdf dfdf dfdf dfdf
Chapter 53: Vitamins and Minerals ................................................................................................... 286
dfdf dfdf dfdf dfdf
Chapter 54: Anemia Drugs .................................................................................................................. 292
dfdf dfdf dfdf
Chapter 55: Nutritional Supplements ................................................................................................. 299
dfdf dfdf dfdf
Chapter 56: Dermatologic Drugs ......................................................................................................... 304
dfdf dfdf dfdf
Chapter 57: Ophthalmic Drugs............................................................................................................ 310
dfdf dfdf dfdf
Chapter 58: Otic Drugs ....................................................................................................................... 315
dfdf dfdf dfdf
, Chapter 01: The Nursing Process and Drug Therapy
dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf d f d f
4
d f d f
Chapter 01: The Nursing Process and Drug Therapy
dfdf dfdf dfdf dfdf dfdf dfdf dfdf
MULTIPLE CHOICE dfdf
1. The nurse is writing a nursing diagnosis for a plan of care for a patient who
dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf
has been newly diagnosed with type 2 diabetes. Which statement reflects the
dfdf dfdf dfdf df df df df dfdf dfdf df df df df df df dfdf df df
correct format for a nursing diagnosis?
dfdf df df dfdf dfdf dfdf dfdf
a. Anxiety
b. Anxiety related to new drug therapy dfdf df df df df df df dfdf
c. Anxiety related to anxious feelings about drug therapy, as evidenced by
dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf
statements such as “I’m upset about having to test my blood sugars.”
dfdf dfdf df df df df dfdf dfdf df df df df df df dfdf dfdf dfdf
d. Anxiety related to new drug therapy, as evidenced by statements such
dfdf dfdf dfdf dfdf dfdf dfdf dfdf df df dfdf dfdf
as “I’m upset about having to test my blood sugars.”
dfdf dfdf dfdf dfdf dfdf df df df df dfdf dfdf dfdf
ANS: df df D
Formulation of nursing diagnoses is usually a three-step process. “Anxiety” is missing
dfdf dfdf dfdf dfdf dfdf df df dfdf dfdf dfdf dfdf dfdf
the “related to” and “as evidenced by” portions of defining characteristics. “Anxiety
dfdf dfdf df df df df dfdf dfdf df df dfdf df df df df dfdf df df
related to new drug therapy” is missing the “as evidenced by” portion of defining
dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf
characteristics. The statement beginning “Anxiety related to anxious feelings” is
dfdf dfdf dfdf dfdf dfdf dfdf df df df df dfdf df df
incorrect because the “related to” section is simply a restatement of the problem
dfdf dfdf df df df df dfdf dfdf df df dfdf dfdf df df dfdf dfdf df df
“anxiety,” not a separate factor related to the response.
dfdf dfdf df df dfdf df df dfdf dfdf df df df df
DIF: COGNITIVE LEVEL: Understanding dfdf dfdf
(Comprehension) TOP:
dfdf NURSING PROCESS: df df d f d f dfdf
Nursing Diagnosis
dfdf df df
MSC: NCLEX: Safe and Effective Care Environment: Management of Care
d f d f dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf
2. The patient is to receive oral guaifenesin (Mucinex) twice a day. Today, the nurse
dfdf dfdf dfdf dfdf df df dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf
was busy and gave the medication 2 hours after the scheduled dose was due.
dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf df df dfdf dfdf dfdf dfdf dfdf
What type of problem does this represent?
dfdf dfdf df df df df dfdf df df dfdf
a. “Right time” dfdf
b. “Right dose” dfdf
c. “Right route” dfdf
d. “Right medication” dfdf
ANS: df df A
“Right time” is correct because the medication was given more than 30 minutes
dfdf df df dfdf df df dfdf dfdf dfdf df df dfdf dfdf df df dfdf
after the scheduled dose was due. “Dose” is incorrect because the dose is not
dfdf df df df df df df dfdf dfdf dfdf df df df df df df dfdf dfdf df df df df
related to the time the medication administration is scheduled. “Route” is incorrect
dfdf df df df df df df dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf
because the route is not affected. “Medication” is incorrect because the medication
dfdf dfdf dfdf dfdf dfdf dfdf dfdf df df dfdf dfdf dfdf df df
ordered will not change.
dfdf dfdf dfdf dfdf
DIF: COGNITIVE LEVEL: Applying dfdf dfdf
(Application) TOP:
dfdf NURSING PROCESS: dfdf d f d f dfdf
Implementation
dfdf
MSC: NCLEX: Safe and Effective Care Environment: Safety and Infection Control
d f d f dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf
3. The nurse has been monitoring the patient’s progress on a new drug regimen since
dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf dfdf
the first dose and documenting the patient’s therapeutic response to the medication.
dfdf dfdf dfdf dfdf df df dfdf dfdf dfdf dfdf dfdf dfdf dfdf
Which phase of the nursing process do these actions illustrate?
dfdf df df df df dfdf dfdf dfdf df df dfdf dfdf df df
a. Nursing diagnosis dfdf
